Avita Medical (ASX:AVH) said interim results from its Cohealyx-I multi-center study showed a reduction of nearly 20 days in the mean time to skin grafting, at 13.6 days compared with a 33.2-day real-world benchmark, for patients with full-thickness wounds, according to a Wednesday Australian bourse filing.

The study's primary endpoint is time to autografting, and the secondary endpoints include wound healing and safety outcomes, per the filing.

The company said the interim analysis of 40 patients showed a median time to grafting of 11 days, with grafting achieved as early as five days, 25% of patients grafted within seven days, and 72% grafted within 14 days.

The study is ongoing, with the full dataset expected this year.